Neuroprotection by eIF2α-CHOP inhibition and XBP-1 activation in EAE/optic neuritis

Haoliang Huang1,5, Linqing Miao2,5, Feisi Liang2, Xiaodong Liu2, Lin Xu2, Xiuyin Teng2, Qizhao Wang1, William H Ridder III3, Kenneth S Shindler4, Yang Sun1 and Yang Hu1.

No therapies exist to prevent neuronal deficits in multiple sclerosis (MS), because the molecular mechanism responsible for the progressive neurodegeneration is unknown. We previously showed that axon injury-induced neuronal endoplasmic reticulum (ER) stress plays an important role in retinal ganglion cell (RGC) death and optic nerve degeneration in traumatic and glaucomatous optic neuropathies. Optic neuritis, one of the most common clinical manifestations of MS, is readily modeled by experimental autoimmune encephalomyelitis (EAE) in mouse. Using this in vivo model, we now show that ER stress is induced early in EAE and that modulation of ER stress by inhibition of eIF2α-CHOP and activation of XBP-1 in RGC specifically, protects RGC somata and axons and preserves visual function. This finding adds to the evidence that ER stress is a general upstream mechanism for neurodegeneration and suggests that targeting ER stress molecules is a promising therapeutic strategy for neuroprotection in MS. Cell Death and Disease (2017) 8, e2936; doi:10.1038/cddis.2017.329; published online 20 July 2017

Multiple sclerosis (MS) is a common inflammatory demyelinating disease and the most frequent chronic neurologic disease of young adults.1 Devastating symptoms include dysfunctions in vision, movement and cognition, which are manifested in a relapsing-remitting and/or a chronic-progressive pattern.1 Countering the inflammation with immunomodulatory reagents is currently the main therapeutic strategy. This approach effectively reduces inflammation and the severity of acute attacks, but has been much less effective in preventing ongoing neurodegeneration and disability.2 An unknown injurious mechanism triggered by inflammatory demyelination of axons may be responsible for axon degeneration, which ultimately leads to retrograde neuronal death and irreversible neurological deficits.3 Neuroprotectants have long been sought in MS, but, as in other chronic neurodegenerative diseases, none has been found. The significant clinical need for neuroprotectants compels us to look for the molecular mechanism that mediates neurodegeneration in MS.

Endoplasmic reticulum (ER) stress has emerged as a possible molecular mechanism of neurodegeneration.4-8 When the ER is overwhelmed by unfolded and misfolded proteins, cells experience ER stress and activate a complex cascade of reactions, in general called the unfolded protein response (UPR).5,9 Three ER-resident stress-sensing proteins initiate three evolutionarily conserved UPR pathways: protein kinase RNA-like ER kinase (PERK), inositol-requiring protein-1 (IRE1α) and activating transcription factor-6 (ATF6). IRE1α, a bi-functional enzyme that contains both a Ser/Thr kinase domain and an endoribonuclease domain, mediates the splicing of X-box binding protein 1 (XBP-1) mRNA to generate an active (spliced) form of the transcription factor, XBP-1s. The IRE1α-XBP-1s pathway targets genes that increase ER protein-folding capacity and facilitate degradation of misfolded proteins through ER-associated protein degradation (ERAD). ATF6 is cleaved sequentially by site-1 protease and site-2 protease in Golgi to generate an active transcription factor ATF6 fragment (ATF6f). ATF6f acts alone or forms heterodimers with XBP-1s to induce expression of ER chaperones to promote protein folding and protein degradation through ERAD, which is generally considered cytoprotective.10,11 Interestingly, mutation of ATF6 causes achromatopsia, a cone degeneration disease; and ATF6 deletion mice develop rod and cone dysfunction with aging.12 PERK phosphorylates and inactivates eukaryotic translation initiation factor 2α (eIF2α) to attenuate global mRNA translation and therefore reduce protein load on the ER. However, phosphorylated eIF2α (eIF2α-P) induces the expression of a pro-apoptotic molecule, C/EBP homologous protein (CHOP), by selectively activating translation of transcription factor ATF4. As a negative feedback mechanism, ATF4 and CHOP induce expression of growth arrest and DNA-damage-inducible protein 34 (GADD34) to facilitate dephosphorylation of eIF2α-P and resume global mRNA translation. CHOP mediates ER stress-induced apoptosis through down-regulating anti-apoptotic Bcl2, upregulating pro-apoptotic BH-3-only molecules Bim and PUMA,5 and increasing expression of death receptor 5 (DR5) and caspase 8 cleavage.13 CHOP also can form heterodimers with ATF4 to cause cell death by upregulating protein synthesis and inducing oxidative stress.14 Inhibition of CHOP is beneficial in many disease models.5 A critical phenomenon of ER stress, which may contribute to the pathogenesis of many disorders,
includes the early and transient but protective IRE1α-XBP-1 and ATF6 activation versus the late and persistent but pro-apoptotic PERK-CHOP activation during chronic ER stress. Consistent with the theme that sustained activation of the PERK-CHOP pathway in prolonged ER stress causes cell death, previous studies from our laboratory revealed that traumatic injury of the optic nerve (ON) causes sustained CHOP expression, but transient XBP-1s expression, in retinal ganglion cells (RGCs); and that reversal of these processes by deletion of CHOP and activation of XBP-1 synergistically protects RGC somata and axons, and preserves visual function in a mouse glaucoma model. About 25% of MS patients have optic neuritis as the initial symptom, 70% have it during the course of the disease and about one-third suffer persistent visual symptoms due to ON degeneration and RGC death. In contrast with other parts of CNS damaged in MS, the pathology and functional deficits of retina/ON injury are more clinically apparent and quantifiable. Therefore multiple clinical trials have used optic neuritis to test neuroprotective therapy. The rodent experimental autoimmune encephalomyelitis (EAE) model replicates many clinical symptoms and pathological signs of MS, including optic neuritis and significant RGC soma and axon loss. In the present studies we take advantage of the accessible structures and clear functional readout of the EAE/optic neuritis model, and demonstrate that manipulating these two UPR pathways, PERK-CHOP pathway and IRE1α-XBP-1 pathway, provides neuroprotection and preservation of visual function. These results indicate that ER stress is the common upstream signal that triggers the degeneration cascade in both neuronal soma and axon in diverse CNS axonopathies. These insights will help to develop innovative and efficient neuroprotective treatments by encouraging targeting of UPR pathways.

**Results**

The time course of optic neuritis and RGC/ON degeneration in EAE. EAE was induced by immunizing 9-week-old female C57BL/6 mice with myelin oligodendrocyte glycoprotein (MOG). Female mice of this age show a higher incidence of optic neuritis than younger male mice. We observed a distribution of clinical scores that is typical of EAE mice after MOG immunization: the paralysis symptoms started around day 11, peaked around day 20 and plateaued for the next several weeks (Figure 1a). We then examined inflammatory cell infiltration and demyelination in ON at different time points after EAE induction. Optic neuritis began at 2 weeks post immunization (2WPI) and peaked at 3WPI, which is evidenced by the infiltration of inflammatory cells in ON stained with hematoxylin and eosin (H&E) and also recognized by microglial marker Iba1 and T cell marker CD3 (Figure 1b). ON demyelination indicated by diminished MBP...
staining also peaked at 3WPI (Figure 1b). Significant RGC soma loss was detected later at 5 and 8WPI by quantification of surviving RGC somata in whole-mount retinas (Figures 2a and b). RGC axons are damaged earlier in EAE than RGC somata, as significant axon loss in ON semi-thin cross-sections was already detected at 3WPI by 1% para-phenylenediamine (PPD) staining and continued at 5 and 8WPI (Figures 2a and c). Therefore early inflammation and demyelination in ON may be responsible for later RGC soma and axon degeneration.

ER stress is induced in RGCs at an early stage of EAE. ER stress has been detected in brain and spinal cord lesions of human MS patients and of rodents with EAE. We investigated whether ER stress is also induced in RGCs in EAE than RGC somata, as significant axon loss in ON semi-thin cross-sections was already detected at 3WPI by 1% para-phenylenediamine (PPD) staining and continued at 5 and 8WPI (Figures 2a and c). Therefore early inflammation and demyelination in ON may be responsible for later RGC soma and axon degeneration.

ER stress is induced in RGCs at an early stage of EAE. ER stress has been detected in brain and spinal cord lesions of human MS patients and of rodents with EAE. We investigated whether ER stress is also induced in RGCs in EAE mice. In situ hybridization revealed increased CHOP and BiP mRNA expression in the ganglion cell layer of retina sections at 1 and 2WPI (Figures 3a and b). Immunohistochemistry confirmed these observations, showing increased levels of CHOP and phosphorylated eIF2α (eIF2α-P) in TuJ1+ RGCs (Figures 3c–e), although the increase of CHOP at 2WPI did not reach statistical significance. We were unable to detect increase of CHOP and eIF2α-P in RGCs at later time points (data not shown). These results indicate that EAE induces ER stress in RGCs at early time points, before axon degeneration and neuronal cell death.

CHOP deletion and XBP-1 activation promote RGC soma and axon survival in EAE. Our previous studies raise the possibility that ER stress is a common neuronal response to disturbances in axonal integrity, and that the underlying neuronal degeneration mechanism may be similar in inflammatory demyelination-induced axon injury. That EAE induces ER stress in RGCs at early time points suggests that ER stress causes optic neuritis-induced neurodegeneration. To explore this possibility, we asked whether manipulating neuronal intrinsic ER stress in RGCs provides effective neuroprotection in EAE/optic neuritis. We and others have found that adeno-associated virus 2 (AAV2) preferentially infects RGCs and produces sustained transgene expression after intravitreal injection. Therefore we intravitreally injected AAV2-XBP-1s into WT and CHOP KO mice 2 weeks before MOG immunization and compared these mice with mock-injected mice. Compared to about 54.3% RGC and 35.5% ON survival in WT EAE mice at 5 WPI, RGC and ON survival was significantly increased in CHOP KO mice and in WT mice overexpressing XBP-1s, and further increased to about 86% RGC and 71.9% ON survival in CHOP KO mice.
with XBP-1s overexpression (Figure 4). WT mice and CHOP KO mice with XBP-1s overexpression showed no significant difference in ON demyelination or Iba1+ inflammatory cells infiltration (Supplementary Figure 1). Therefore, as in glaucoma, manipulation of these two ER stress pathways in opposite directions specifically in RGCs promotes RGC soma and axon survival in EAE/optic neuritis.

Neuroprotection achieved by blocking CHOP upstream molecule eIF2α-P in EAE. To further confirm that the CHOP pathway plays a detrimental role in EAE/optic neuritis, we conducted a similar analysis to test whether blocking the CHOP upstream regulator eIF2α-P specifically in RGCs also provides neuroprotection. We injected AAV2-Cre intravitreally to the eIF2α A/A mouse,31 which removed the floxed WT eIF2α transgene specifically from RGCs and could be identified by its expression of GFP as an indicator, and achieved temporally controlled expression of unphosphorylated eIF2α S51A mutant in RGCs. This strategy has been used to confirm that AAV-Cre mediated eIF2α S51A mutant expression in RGCs results in CHOP inhibition and protects RGC somata and axons in ON crush and glaucoma models.19 Expression of unphosphorylated eIF2α S51A mutant in RGCs significantly increased RGC soma and axon survival in EAE (Figure 5), which confirms that inhibiting the eIF2α-CHOP pathway provides neuroprotection. Mice with different genetic conditions showed no significant difference in EAE clinical scores (Supplementary Figure 2).

eIF2α-CHOP inhibition and XBP-1 activation also preserve visual function in EAE. The clinical significance of neuroprotection depends on functional preservation. The visual evoked potential (VEP) is a gross electrical signal recorded from visual cortex after flash stimulation of the eye.32 Because the VEP signal depends on the integrity of the entire visual pathway, including RGC somata and ON axons, it provides readout of the physiological function of both structures. VEP recording has been used to estimate loss of RGCs and axons in several optic neuropathy models.33–35 Notably, delayed VEP latencies correlate with ON
demyelination and axon loss in MS patients. We recorded the VEP from mice 1 week before MOG immunization (baseline) and at 5 WPI (end point). Because the variation of P1-N1 amplitude was too big to be used in this model, we focused on the more stable N1 and P1 latencies. In contrast to sham mice with constant N1 and P1 latencies (Figure 6a), N1 and P1 latencies were significantly prolonged in WT mice with EAE (Figure 6b); these changes were much smaller in CHOP KO mice injected with AAV-XBP-1s (Figure 6c) and in eIF2αA/A mice injected with AAV-Cre+AAV-XBP-1s (Figure 6d). These changes of latencies (ΔN1 or P1 = 5 WPI−baseline) were significantly different in WT mice and mice with eIF2α−CHOP inhibition+XBP-1 activation (Figures 6e and f), indicating that ER stress manipulation preserves visual function.

Delayed eIF2α−CHOP inhibition and XBP-1 activation also provide neuroprotection and preserve visual function in EAE. Current immunomodulatory agents effectively reduce inflammation and autoimmune damage in MS, but they fail to prevent progressive neurodegeneration and disability. For an experimental neuroprotection treatment to be clinically relevant, it must be effective when administered after the onset of disease. To simulate the clinical setting, we tested whether manipulating ER stress only after MOG immunization also protects RGC somata and axons. We have used AAV2-CHOP shRNA to directly knock down CHOP levels in RGCs and demonstrated that it protects RGC somata and axons in ON crush and glaucoma models. We therefore injected AAV2-CHOP shRNA+AAV2-XBP-1s or AAV2-scramble shRNA+AAV2-GFP (control) into WT mice 3 days after MOG immunization. Because AAV-mediated gene expression in RGCs normally takes at least 2 weeks after infection, CHOP inhibition and XBP-1 activation are likely to occur 2–3 weeks after MOG immunization. Interestingly, this delayed ER stress modulation significantly protected RGC somata and axons (Figures 7a and b) and significantly decreased the prolonged N1 latency but not P1 latency (Figure 7c). Similarly, eIF2α A/A mice injected with AAV-Cre+AAV-XBP-1s 3 days after MOG immunization, also showed RGC soma and axon protection and even better preservation of visual function (Figure 7). Importantly, injecting WT mice with AAV-CHOP shRNA+AAV-XBP-1s 1 week after MOG immunization provided no neuroprotection or visual function.
preservation (Supplementary Figure 3). These results suggest that the treatment window is limited in the first 2 weeks of EAE in mouse.

Discussion

By exploiting the anatomical and technical advantages of the optic neuritis mouse model, we confirmed that EAE/optic neuritis induces neuronal ER stress in RGCs. As in traumatic and glaucomatous optic neuropathies, eIF2α-CHOP inhibition and XBP-1 activation preserve the morphology and function of both RGC somata and axons after inflammatory demyelination of ON. These results demonstrate that the PERK-eIF2α-CHOP branch of UPR in neurons plays an important role in autoimmune-induced neurodegeneration, and that combined inhibition of this pathway and activation of the XBP-1 pathway is a promising therapeutic approach for MS. This study provides additional evidence that neuronal intrinsic ER stress commonly contributes to neurodegeneration and demonstrates the therapeutic potential of targeting neuronal intrinsic UPR pathways in diverse CNS axonopathies.

A previous study found that although EAE induces ER stress in mouse spinal cords, the behavioral rating score did not improve in CHOP KO mice. Unfortunately, because this study did not examine the spinal cords histologically for neuropathological changes, it lacks morphological evidence concerning neuronal and oligodendrocyte survival in CHOP KO mice with EAE. Indeed, activation of the CHOP upstream molecule PERK in oligodendrocytes is protective in EAE. The absence of this cell-specific information makes it impossible to interpret why the behavioral deficits did not improve in CHOP KO mice: is CHOP irrelevant or did positive and negative effects of CHOP on neuronal, axonal and oligodendrocyte survival cancel themselves out? Since germ line KO deletes CHOP from all cell populations, the specific cell type that contributes to this phenotype cannot be determined. Our studies using CHOP KO mice also cannot rule out the possibility that CHOP deletion in non-neuronal cells contributes to the protection of RGCs. However, our positive data from eIF2α A/A mice and WT mice injected with AAV-CHOP shRNA suggest that neuronal intrinsic inhibition of the eIF2α-CHOP pathway is neuroprotective.
The mechanism that induces ER stress in axonopathies is unknown. Release of calcium from intra-axonal smooth ER is an important early event after axon injury that correlates with initiation of axon degeneration, possibly by promoting cytoskeleton disintegration and mitochondrial dysfunction. Of note, disturbance of calcium homeostasis is a major inducer of ER stress. However, it remains to be determined whether inflammatory demyelination in MS disturbs axonal calcium level.

Modulation of ER stress also protects injured neurons and improves functional recovery in experimental spinal cord injury, stroke, Alzheimer disease, Parkinson’s disease, amyotrophic lateral sclerosis, prion disease and, most relevantly, retinal cell degenerations, including RGC and photoreceptor. Importantly, recent reports provide evidence of ER stress in brain and spinal cord lesions of human MS patients and rodent EAE, suggesting the importance of ER stress in the pathophysiology of MS. However, previous studies showed that PERK activation in oligodendrocytes promotes their survival in EAE and suggest that ER stress in oligodendrocytes is beneficial in demyelinating diseases. In contrast to its beneficial role in oligodendrocyte survival, we found that neuronal intrinsic ER stress is injurious to neurons in EAE, as in ON trauma and glaucoma. Therefore, we propose to target the UPR pathways in neurons and oligodendrocytes differently to antagonize the neurodegeneration in MS. Furthermore, the combination of neuroprotective and anti-inflammatory therapeutic strategies may improve the long-term clinical outcome of MS/optic neuritis.

Materials and Methods
Animals. CHOP KO and C57BL/6J WT mice were purchased from Jackson Laboratories (Bar Harbor, Maine, USA). eIF2α A/A mice were described before. All mice had a C57BL/6J background. For all surgical and treatment comparisons, control and treatment groups were prepared together in single cohorts, and the experiment repeated at least twice. All experimental procedures were performed in...
compliance with animal protocols approved by the IACUC at Temple University School of Medicine and APLAC at Stanford University, CA, USA.

EAE/autoimmune optic neuritis model. Since young mice and male mice are relatively resistant to EAE, we used 8–9-week-old female mice with C57BL/6 background. EAE/optic neuritis was induced by immunization with 150 μg MOG35-55 peptide emulsified with complete Freund’s adjuvant (CFA) and 2.5 mg/ml Mycobacterium tuberculosis, followed by injection of 200 ng pertussis toxin at day 0 and day 2. The MOG/CFA mixture was injected subcutaneously at the back of the neck and the base of the tail. Intraperitoneal injection of pertussis toxin in PBS was

**Figure 7** Delayed ER stress manipulation provides neuroprotection and preserves visual function of RGC and ON in EAE mice. (a) AAV-CHOP shRNA+AAV-XBP-1s or AAV-Cre+AAV-XBP-1s were injected intravitreally at 3 days post immunization in WT mice and eIF2α A/A mice, respectively. Upper panel, confocal images of flat-mounted retinas showing surviving TuJ1 positive (red) RGCs at 8 WPI. Scale bar, 20 μm. Lower panel, light microscope images of semi-thin transverse sections of ON with PPD staining at 8 WPI. Scale bar, 10 μm. (b) Quantification of surviving RGC somata and axons, represented as percentage of surviving RGCs or axons in the EAE mouse eyes, compared to the sham control mouse eyes. (c) The differences in the flash VEP responses between 1 week before and 7 weeks after MOG immunization are represented as ΔN1 latency and ΔP1 latency elicited by a series of stimulus light intensities. All quantification data are presented as means ± S.E.M., WT, n = 14; CHOP shRNA+XBP-1s, n = 14; eIF2α A/A+XBP-1s, n = 10, *P<0.05, **P<0.01, ***P<0.001; two-way ANOVA with Bonferroni’s post hoc test.
used to break down the blood-brain barrier. Mice injected with the same volume of CFA emulsion without MOG were used as sham controls. The behavioral deficits of these mice were assessed daily with a 5-point scale: 5.0; no disease; 0.5; tail paralysis; 1.0; partial tail paralysis; 1.5; tail paralysis and waddling gait = 2.0; partial limb paralysis = 2.5; paralysis of one limb = 3.0; paralysis of one limb and partial paralysis of another = 3.5; paralysis of two limbs = 4.0; moribund state = 4.5; and death = 5.0. The clinical score was recorded every day from day 9 to day 14 and twice weekly thereafter until end point.

Paraffin sections and immunostaining of the eyes. After transcardiac perfusion with 4% paraformaldehyde (PFA) in PBS, the eyes and ONs were dissected out and post-fixed with 4% PFA for 24 h, at 4°C (the lens was extracted after 1 h). The samples were then transferred to sample cassettes, washed in PBS, dehydrated and infiltrated with paraffin in a Shandon Cital 1000 Tissue Processor (Thermo Fisher Scientific, Waltham, MA, USA). Paraffin sections (9 μm) were cut, dehydrated, and incubated with blocking medium (10% goat serum, 0.1% Triton X-100 in PBS) for 1 h at room temperature. Mouse anti-Iba1 (1:200 dilution, Wako, Richmond, VA, USA), rabbit anti-CD3 (1:100 dilution, Bio-Rad, Hercules, CA, USA), rabbit anti-MBP (1:200 dilution, Covance, Princeton, NJ, USA), FluoroMyelin (1:300 dilution, Thermo Fisher Scientific), mouse anti-CHOP (clone 9C8, 1:200 dilution; Thermo Fisher Scientific), rabbit anti-phospho-eIF2α Ser51 (119A11, 1:200 dilution, Cell Signaling, Beverly, MA, USA) and mouse or rabbit neuronal class β-III tubulin (cloneTu1, 1:500 dilution; Covance) were diluted in the same blocking buffer. The slides were incubated with primary antibodies overnight at 4°C, washed three times for 10 min each wash with PBS and incubated in secondary antibodies (Cy2, Cy3 or Cy5-conjugated, 1:200; Jackson ImmunoResearch, West Grove, PA, USA) for 1 h at room temperature. Slides were again washed three times for 10 min each wash with PBS before a cover slip was attached with Fluoromount-G (SouthernBiotech, Birmingham, AL, USA).

In situ hybridization. After mice were perfused with ice-cold 4% PFA/PBS, eyes were dissected out and fixed in 4% PFA/PBS at 4°C overnight. The eyes were dehydrated with increasing concentrations of sucrose solution (15–30%) overnight before embedding in OCT on dry ice. Serial cross sections (12 μm) were cut with a Leica cryostat and collected on Superfrost Plus Slides. The sections were washed twice for 10 min in DEPC-treated PBS and permeabilized twice in 0.1% Tween/PBS for 10 min. After blocking at 50°C for 1 h with hybridization buffer (50% formamide, 5 × SSC, 100 μg/ml yeast RNA, 100 μg/ml wheat germ tRNA, 50 μg/ml heparin and 0.1% Tween in DEPC H2O), the sections were hybridized with 2 μg biotin-labeled antisense probes at 50°C overnight. The sections were washed three times at 55°C for 10 min with hybridization buffer, 0.1% Tween/PBS, and then blocked in PBS blocking buffer containing 0.1% Tween/PBS. The sections were washed with 0.1 M PB three times, 10 min each wash. The ONs were then carefully dissected out and rinsed with 0.1 M PB three times, 10 min each wash. They were then incubated in 1% osmium tetroxide in 0.1 M PB for 1 h at room temperature followed by washing with 0.1 M PB for 10 min and water for 5 min. ONs were then dehydrated through a series of graded ethanol (50–100%), rinsed twice with propylene oxide (PO), 3 min each rinse, and transferred to medium containing 50% EMbed 812 / 50% PO. overnight. Next day, the medium was changed to a 2:1 ratio of EMbed 812/PO. ONs remained in this mixture overnight, then were transferred to 100% EMbed 812 on a rotator for another 6 h, embedded in a mold filled with 100% EMbed 812 and incubated at 60°C overnight. Semi-thin sections (1 μm) were cut on a ultramicrotome (MT UltraCut, Leica, Wetzlar, Germany) and the transverse sections of ON were collected 1 mm distal to the eye. The semi-thin sections were attached to glass slides and stained with 1% PPD in methanol: isopropanol (1:1) for 35 min. After rinsing three times with methanol: isopropanol (1:1), coverslips were applied with PermMount mounting medium (Electron Microscopy Sciences, Hatfield, PA, USA). PPD stains all myelin sheaths, but darkly stains the axoplasm only of degenerating axons, which allows us to differentiate surviving axons from degenerating axons.65

Quantification of surviving axons. The semi-thin sections were viewed through a ×100 lens of a Nikon microscope with a total amplification of ×1000. Sequential images were taken so as to cover the entire area of the ON without overlap. An area of 21.6 μm × 29 μm was cropped from the center of each image, and the surviving axons within the designated area were counted. After counting all the images taken from a single nerve, the mean of the surviving axon number was calculated for each ON. The mean of the surviving axon number in the injured ON was compared to that in the contralateral control ON to yield a percentage of axon survival value. Counts of surviving axons were performed by a single observer who was blinded with regard to the surgical manipulations and treatments.

Skull screw implant for VEP measurement. 7 week-old mice were anesthetized with xylazine and ketamine (0.01 mg xylazine/g+0.08 mg ketamine/g). Sterile ophthalmic ointment (Akorn) was applied to protect the eyes during the procedure. The head was shaved, and a scalp incision was made from the mid line between the ears to 5 mm in front of bregma. After exposing the skull, three small burr holes were drilled with a 0.5 mm micro-drill (Ideal micro-drill, Cellpoint Scientific, Gaithersburg, MD, USA) 2 mm rostral to bregma (reference electrode) and two were drilled 2.5 mm horizontal to lambda (overlying the primary visual cortex, for the active electrodes). Three stainless steel screws (M0.8 X 0.120 SL, FILLSS, PN: NAS721CE50-120, Antrim Miniature Specialties Inc, Fallbrook, CA, USA) were mounted in the holes and sealed with dental cement, 0.5 mm of their tips were inside the skull. The scalp was closed with surgical sutures to cover the edge of the cement. Antibiotic ointment was applied to the wound after surgery to prevent contamination. Mice recovered for 1 week before the first VEP measurement.
VPE measurements. Mice were anesthetized with xylazine and ketamine. The pupils were dilated by applying 1% tropicamide sterile ophthalmic solution (Akorn). One drop of an artificial tear (Alcon, Fort Worth, TX, USA) was applied regularly to the eyes to keep the cornea moist and prevent cataract formation throughout the procedure. The mice were kept in the dark for 5–10 min before the measurement. Therefore, the VPE measurement always began 25 min after the mice were anesthetized. The right eye was examined first; the left eye was occluded with black tape. One alligator clip was attached to the active electrode over the left visual cortex and another to the reference electrode. Mice were placed in the gantry of the VEP instrument (RETi-port, Roland Consult, Havel, Germany) in a dark room; body temperature was maintained at 37 °C using a feedback-controlled heating pad (Physitemp Instruments Inc., Clifton, NJ, USA). The VEP was recorded in response to a series of white light flashes of graded intensity from 0.030 cd/m² to 3.0 cd/m². The flashes were presented at a frequency of 1 per second (1 Hz) and 30 flashes were averaged for a response. After recording from the right eye was complete, the black tape was removed from the left eye and placed over the right eye, and the alligator clip was moved from the left to the right side of the visual cortex. The VEP of the left eye was recorded under the same conditions as the right eye. After recording, the black tape was removed and antibiotic ointment (Akorn) applied to the eyes. The first positive peak in the VEP waveform was designated as P1 and the next peak as N1. The latency of P1 or N1 and the P1-N1 amplitude were measured one week before MOG immunization as a baseline and at the end point of 5WPI. The differences between the baseline and end point recordings under different stimulation intensities were calculated and referred to as Δ P1 latency, Δ N1 latency and Δ P1-N1 amplitude.

Statistics. Data are presented as means ± S.E.M. We used Student’s t-test for two-group comparison, one-way ANOVA with Bonferroni’s post hoc test for multiple comparisons (≥3 groups) with one variance and two-way ANOVA with Bonferroni’s post hoc test for multiple comparisons (≥3 groups) with two variances.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements. We would like to thank Drs Michael Selzer, Jeffrey Goldberg, Zhigang He and Alan Tessler for critically reading the manuscript. YH is supported by grants from NIH EY022926 and EY024932, BrightFocus Foundation G2013048, Fight for Sight FFS-GIA-13-008, National Multiple Sclerosis Society RG5021A1/1 and support from Research to Prevent Blindness, Inc. LM is supported by a Postdoctoral Fellowship from Shriners Hospitals for Children. Portions of this work were supported by NIH grant EY015014 and Research to Prevent Blindness to KSS and NIH grant EY25295 to YS.

1. Frohman EM, Racke MK, Raine CS. Multiple sclerosis—the plaque and its pathogenesis. Nature Med 2006; 12: 942–955.
2. Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol 2015; 14: 208–223.
3. Traka M, Podojil JR, McCarthy DP, Miller SD, Popko B. Oligodendrocyte death results in inflammatory demyelination. J Neurosci 2016; 36: 15381–15391.
4. Lin W, Popko B. Endoplasmic reticulum stress in disorders of myelinating cells. Cell Death and Disease 2015; 6: e1793.
5. Hirata T, Sato T, Miki A, Tanaka S, Takanashi J, Hori T et al. Comparative analysis of ER stress response pathways on axon injury-induced death of retinal ganglion cells. J Cell Biol 2012; 199: 1093–1104.
6. Liu Y, Park KK, Yang L, Wei X, Yang Q, Cho KS et al. Differential effects of unfolded protein response pathway on axon injury-induced death of retinal ganglion cells. Neuroreport 2012; 23: 645–648.
7. Smith HL, Mallucci GR. The unfolded protein response: mechanisms and therapy of human disease. Nat Rev Mol Cell Biol 2013; 14: 625–636.
8. Deslauriers AM, Afkhami-Goli A, Paul AM, Bhat RK, Acharjee S, Ellestad KK et al. ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. Nat Cell Biol 2015; 17: 946–958.
9. Lin JH, Li H, Yang L, Huang H, Liang F, Teng X et al. Rescue of glaucous demyelination by differentially modulating neuronal endoplasmic reticulum stress molecules. J Neurosci 2016; 36: 5981–5993.
10. Balcer LJ, Miller DH, Reingold SC, Cohen JA. Vision and vision-related outcome measures in multiple sclerosis. Brain 2015; 138(Pt 1): 11–27.
11. Akins D, Abrecht P, Hartung HP. Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis: update on current trials and perspectives. Curr Opin Neurol 2016; 29: 199–204.
12. Kohl S, Zobor D, Chiang WC, Weisschuh N, Staller J, Gonzalez Menendez I et al. Mutations in the unfolded protein response regulator A TF6 cause the cone dysfunction disorder achromatopsia. Nat Genet 2015; 47: 757–765.
13. Lu M, Lawrence DA, Marsters S, Acosta-Alvear D, Kimmig P, Mendez AS et al. Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis. Science 2014; 345: 98–101.
14. Han J, Back SH, Hur J, Lin YH, Gildersleeve R, Shan J et al. ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. Nat Cell Biol 2013; 15: 481–490.
15. Rokutowski DT, Arnold SM, Miller CN, Wu J, Li J, Gunnison KM et al. Adaptation to ER stress is mediated by differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins. PLoS Biol 2006; 4: e374.
Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)